Diabetologia (2017) 60:1620–1629 DOI 10.1007/s00125-017-4337-9 REVIEW Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes 1,2 1 1 Simon J. Griffin & James K. Leaver & Greg J. Irving Received: 21 April 2017 /Accepted: 24 May 2017 /Published online: 2 August 2017 The Author(s) 2017. This article is an open access publication Abstract control. Summary estimates were based on a small number of Aims/hypothesis Metformin is the most-prescribed oral med- events: 416 myocardial infarctions/ischaemic heart disease ication to lower blood glucose worldwide. Yet previous sys- events in seven studies and 111 strokes in four studies. The tematic reviews have raised doubts about its effectiveness in UK Prospective Diabetes Study (UKPDS) contributed the ma- reducing risk of cardiovascular disease, the most costly com- jority of data to the summary estimates, with weights ranging plication of type 2 diabetes. We aimed to systematically iden- from 52.3% for myocardial infarction to 70.5% for stroke. All tify and pool randomised trials reporting cardiovascular out- outcomes, with the exception of stroke, favoured metformin, comes in which the effect of metformin was ‘isolated’ through with limited heterogeneity between studies, but none achieved comparison to diet, lifestyle or
Diabetologia – Springer Journals
Published: Aug 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera